Vivesto AB · OMXSTO:VIVE
Vivesto AB — Oasmia Pharmaceutical — Corporate Update (May 2020)
12 slides from Vivesto AB's corporate update, May 2020
Slide 1: Oasmia Pharmaceutical AB Strategic Update
OASMIA PHARMACEUTICAL AB STRATEGIC UPDATE Francois Martelet M.D. Chief Executive Officer May 2020 1
Slide 2: Forward looking statement
Forward looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company Founded in 1999 NASDAQ Stockholm 2010 HQ Uppsala, Sweden Market Cap approx. SEK 3,58 B XR17™ technology platform, allowing nano-sized particle R&D and GMP-certified formulations of APIs, to be soluble in production facility in Uppsala,
Slide 4: New leadership taking Oasmia to next level
New leadership taking Oasmia to next level ANETTE SJÖDIN ELIN TRAMPE Chief Business Officer Chief Technical Officer and deputy CEO Previous experience: Previous experience: Many years experience in More than 25 years of leading positions within Supply experience from global Chain, Project Management
Slide 5: Strategic review – unlocking Oasmia's full potential
Strategic review – unlocking Oasmia’s full potential Strategic review launched by Board following appointment of new CEO in March 2020 Global commercial partnership for Apealea® with Elevar Therapeutics transforms Oasmia’s prospects and enables refocusing of priorities Proprietary XR17™ solubility-e
Slide 6: XR17 improves solubility, a significant concern for drug development
Oasmia’s XR17™ improves solubility that is a significant concern for drug development and marketed drugs LOW WATER SOLUBILITY AFFECTS SOLUBILITY ENHANCERS CAN CAUSE C.40% OF APPROVED DRUGS AND SERIOUS ADVERSE SIDE EFFECTS OR C.90% OF PIPELINE DRUGS REQUIRE USE OF ADDITIONAL DRUGS API XR17™ XR17™ + A
Slide 7: XR17 – multiple opportunities in oncology, human and animal health
XR17TM – multiple opportunities in oncology, human and animal health XR17™ ANIMAL ONCOLOGY OTHER TAs HEALTH Lung Cervical cancer cancer Prostate Breast Ovarian Bladder cancer cancer cancer cancer 7
Slide 8: Building a diverse portfolio based on XR17 platform technology
Building a diverse portfolio based on XR17™ platform technology Registration / Product Indication Pre-clinical Phase I Phase II Phase III approval Geography Ovarian cancer Pre-NDA meeting USA Ovarian cancer EU / EEA1 Apealea / Paclical Ovarian cancer Russia (paclitaxel) Ovarian cancer Kazakhstan Met
Slide 9: Apealea – transformative partnership worth up to $698m + royalties
Apealea® – transformative partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB Upfront payment $20M Double digit royalties on global Apealea sales % Milestones based on regulatory and sales achievements $678M Oasmia retains sole contr
Slide 10: Strategic review - maximizing existing resources
Strategic review - maximizing existing resources • Cost control program to free up resources to invest in future growth • Reflects changed priorities post Elevar Therapeutics agreement • Key goals: • Annualised cost savings of more than SEK 100 million • A ~50% reduction in the cash burn rate to bel
Slide 11: Oasmia's goal is to deliver long-term profitable growth
Oasmia’s goal is to deliver long-term profitable growth • Explore additional opportunities to apply Platform to build a cash-flow positive XR17™ in oncology / other TAs specialty pharma leader • Drive existing pipeline development ‒ Docecal (docetaxel) in prostate cancer ‒ XR-19 combination cancer t
Slide 12: Oasmia Pharmaceutical AB
OASMIA PHARMACEUTICAL AB Corporate address: Vallongatan 1, Uppsala 752 28 Sweden For more information visit www.oasmia.com 12